These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 14966093)

  • 41. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer.
    Janku F; Kleibl Z; Novotny J; Tesarova P; Petruzelka L; Matous B
    Neoplasma; 2004; 51(3):204-8. PubMed ID: 15254674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.
    Span PN; Sweep CG; Manders P; Beex LV; Leppert D; Lindberg RL
    Cancer; 2003 Jun; 97(11):2710-5. PubMed ID: 12767082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.
    Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP
    Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
    Foekens JA; Look MP; Bolt-de Vries J; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Jan; 79(2):300-7. PubMed ID: 9888472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR.
    Ntoulia M; Stathopoulou A; Ignatiadis M; Malamos N; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Biochem; 2006 Sep; 39(9):879-87. PubMed ID: 16925986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.
    Ferrucci PF; Rabascio C; Mazzetta C; Cocorocchio E; Agazzi A; Vanazzi A; Cinieri S; Peccatori FA; Paolucci M; Bertolini F; Martinelli G
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6039-46. PubMed ID: 15447988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
    Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
    Licznerska BE; Wegman PP; Nordenskjöld B; Wingren S
    Breast Cancer Res Treat; 2008 Nov; 112(1):15-23. PubMed ID: 18030614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
    Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
    Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR: association with clinical prognostic factors.
    Ferro P; Franceschini MC; Bacigalupo B; Dessanti P; Falco E; Fontana V; Gianquinto D; Pistillo MP; Fedeli F; Roncella S
    Anticancer Res; 2010 Jun; 30(6):2377-82. PubMed ID: 20651396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
    Li BJ; Wang JY; Wang HY; Huang XP; Zhang LJ; Long H; Yang MT; Rong TH
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):766-9. PubMed ID: 17366790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of a three-gene expression signature of poor-prognosis breast carcinoma.
    Bièche I; Tozlu S; Girault I; Lidereau R
    Mol Cancer; 2004 Dec; 3(1):37. PubMed ID: 15606925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.